Shionogi and Tetra expand partnership ahead of Alzheimer’s trial readoutShionogi has expanded its partnership with its Alzheimer’s drug development partner Tetra Therapeutics, giving an option for a Share XShionogi and Tetra expand partnership ahead of Alzheimer’s trial readouthttps://pharmaphorum.com/news/shionogi-and-tetra-expand-partnership-ahead-of-alzheimers-trial-readout/
Biogen and Sangamo work on Parkinson’s and Alzheimer’s gene therapiesBiogen and Sangamo have begun a collaboration to develop gene regulation therapies for neurological diseases including Parkinson’s and Share XBiogen and Sangamo work on Parkinson’s and Alzheimer’s gene therapieshttps://pharmaphorum.com/news/biogen-and-sangamo-work-on-parkinsons-and-alzheimers-gene-therapies/
Warren Buffet shocks Wall Street with Biogen gambleBiogen is trying to resurrect two failed trials of its Alzheimer’s drug aducanumab – and superstar investor Warren Share XWarren Buffet shocks Wall Street with Biogen gamblehttps://pharmaphorum.com/news/warren-buffet-shocks-wall-street-with-biogen-gamble/
Is Tecfidera’s patent win a pyrrhic victory for Biogen?Shares in Biogen jumped last week after the company successfully defended its blockbuster MS drug Tecfidera from a Share XIs Tecfidera’s patent win a pyrrhic victory for Biogen?https://pharmaphorum.com/views-analysis-sales-marketing/tecfideras-patent-pyrrhic-victory-biogen/
Roche and Lilly’s Alzheimer’s drugs draw blanks in inherited diseaseAs Biogen prepares for an FDA review of its amyloid-targeting Alzheimer’s drug aducanumab, Roche and Eli Lilly lifted Share XRoche and Lilly’s Alzheimer’s drugs draw blanks in inherited diseasehttps://pharmaphorum.com/news/roche-and-lillys-alzheimers-drugs-draw-blanks-in-inherited-disease/
Biogen gears up for Alzheimer’s drug launchThere are serious doubts about whether the FDA will approve Biogen’s Alzheimer’s candidate aducanumab – but is gearing Share XBiogen gears up for Alzheimer’s drug launchhttps://pharmaphorum.com/news/biogen-gears-alzheimers/
Alector launches $208m fundraiser for Alzheimer’s R&D with AbbVieAlector has launched an $208 million stock market offering as it ramps up clinical trials with AbbVie into Share XAlector launches $208m fundraiser for Alzheimer’s R&D with AbbViehttps://pharmaphorum.com/news/alector-launches-208m-fundraiser-as/
Four ways AI and machine learning will transform healthcare in 2020From AI assisted robotic surgery to clinical diagnosis, image analysis and administrative tasks, the use of artificial intelligence Share XFour ways AI and machine learning will transform healthcare in 2020https://pharmaphorum.com/digital/four-ways-ai-and-machine-learning-will-transform-healthcare-in-2020/
iPad app could screen entire UK population for Alzheimer’s symptomsHealth technology Medopad has announced a strategic collaboration with Johnson & Johnson’s pharma unit, Janssen, to research and Share XiPad app could screen entire UK population for Alzheimer’s symptomshttps://pharmaphorum.com/news/janssen-and-medopad-aim-to-use-ipad-tool-to-screen-uk-for-alzheimers/
